Regulatory cross-talk between lysine acetylation and ubiquitination: Role in control of protein stability

BioEssays

Volumn 27, Issue 4, 2005, Pages 408-415

  Caron, Cécile ^a   Boyault, Cyril ^a   Khochbin, Saadi ^a  

^a INSTITUT ALBERT BONNIOT   (France)

Author keywords

[No Author keywords available]

Indexed keywords

LYSINE; PROTEASOME;

ACETYLATION; CELL FUNCTION; COMPLEX FORMATION; CROSS LINKING; DATA ANALYSIS; MOLECULAR DYNAMICS; PROTEIN DEGRADATION; PROTEIN STABILITY; REGULATORY MECHANISM; REVIEW; SIGNAL TRANSDUCTION; UBIQUITINATION;

ACETYLATION; HISTONE DEACETYLASES; LYSINE; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEINS; SIGNAL TRANSDUCTION; UBIQUITIN;

EID: 17844385784     PISSN: 02659247     EISSN: None     Source Type: Journal    
DOI: 10.1002/bies.20210     Document Type: Review

References (72)

1. Kouzarides T. 2000. Acetylation: a regulatory modification to rival phosphorylation? EMBO J 15:1176-1179.
2. Yang XJ. 2004. Lysine acetylation and bromodomain: new partnership for signaling. BioEssays 26:1076-1087.
3. Pickart CM, Cohen RE. 2004. Proteasomes and their kin: proteases in the machine age. Nat Rev Mol Cell Biol 5:177-187.
4. Glickman MH, Ciechanover A. 2002. The ubiquitin-roteasome proteolytic pathway: destruction for the sake of construction. Physiol Rev 82:373-428.
5. Marx J. 2002. Cell biology. Ubiquitin lives up to its name. Science 297:1792-1794.
6. Hicke L, Dunn R. 2003. Regulation of membrane protein transport by ubiquitin and ubiquitin-binding proteins. Annu Rev Cell Dev Biol 19:141-172.
7. Schnell JD, Hicke L. 2003. Non-traditional functions of ubiquitin and ubiquitin-binding proteins. J Biol Chem 278:35857-35860.
8. Aguilar RC, Wendland B. 2003. Ubiquitin: not just for proteasomes anymore. Curr Opin Cell Biol 15:184-190.
9. Herrera FJ, Triezenberg SJ. 2004. Molecular biology: what ubiquitin can do for transcription. Curr Biol 14:R622-624.
10. Hochstrasser M. 2004. Ubiquitin signalling: what's in a chain? Nat Cell Biol 6:571-572.
11. Ito A, Kawaguchi Y, Lai CH, Kovacs JJ, Higashimoto Y, et al. 2002. MDM2-HDAC1-mediated deacetylation of p53 is required for its degradation. EMBO J 21:6236-6245.
12. Jin YH, Jeon EJ, Li QL, Lee YH, Choi JK, et al. 2004. Transforming growth factor-beta stimulates p300-dependent RUNX3 acetylation, which inhibits ubiquitination-mediated degradation. J Biol Chem 279:29409-29417.
13. Goel A, Janknecht R. 2003. Acetylation-mediated transcriptional activation of the ETS protein ER81 by p300, P/CAF, and HER2/Neu. Mol Cell Biol 23:6243-6254.
14. Jacob AL, Lund J, Martinez P, Hedin L. 2001. Acetylation of steroidogenic factor 1 protein regulates its transcriptional activity and recruits the coactivator GCN5. J Biol Chem 276:37659-37664.
15. Martinez-Balbas MA, Bauer UM, Nielsen SJ, Brehm A, Kouzarides T. 2000. Regulation of E2F1 activity by acetylation. EMBO J 19:662-671.
16. Ianari A, Gallo R, Palma M, Alesse E, Gulino A. 2004. Specific role for p300/CREB-binding protein-associated factor activity in E2F1 stabilization in response to DNA damage. J Biol Chem 279:30830-30835.
17. Rausa FM 3rd, Hughes DE, Costa RH. 2004. Stability of the hepatocyte nuclear factor 6 transcription factor requires acetylation by the CREB binding protein coactivator. J Biol Chem 279:43070-43076.
18. Steinberg MS, Cohen SN, Weber WW. 1971. Isotope exchange studies on rabbit liver N-acetyltransferase. Biochim Biophys Acta 235:89-98.
19. Butcher NJ, Arulpragasam A, Minchin RF. 2004. Proteasomal degradation of N-acetyltransferase 1 is prevented by acetylation of the active site cysteine: a mechanism for the slow acetylator phenotype and substrate-dependent down-regulation. J Biol Chem 279:22131-22137.
20. Ciechanover A, Ben-Saadon R. 2004. N-terminal ubiquitination: more protein substrates join in. Trends Cell Biol 14:103-106.
21. Kuo ML, den Besten W, Bertwistle D, Roussel MF, Sherr CJ. 2004. N-terminal polyubiquitination and degradation of the Arf tumor suppressor. Genes Dev 18:1862-1874.
22. Arendt CS, Hochstrasser M. 1999. Eukaryotic 20S proteasome catalytic subunit propeptides prevent active site inactivation by N-terminal acetylation and promote particle assembly. Embo J 18:3575-3585.
23. Wang X, Taplick J, Geva N, Oren M. 2004. Inhibition of p53 degradation by Mdm2 acetylation. FEBS Lett 561:195-201.
24. Lee JW, Bae SH, Jeong JW, Kim SH, Kim KW. 2004. Hypoxia-inducible factor (HIF-1)alpha: its protein stability and biological functions. Exp Mol Med 36:1-12.
25. Jeong JW, Bae MK, Ahn MY, Kim SH, Sohn TK, et al. 2002. Regulation and destabilization of HIF-1alpha by ARD1-mediated acetylation. Cell 111:709-720.
26. Chan HM, Krstic-Demonacos M, Smith L, Demonacos C, La Thangue NB. 2001. Acetylation control of the retinoblastoma tumour-suppressor protein. Nat Cell Biol 3:667-674.
27. Hsieh JK, Chan FS, O'Connor DJ, Mittnacht S, Zhong S, et al. 1999. RB regulates the stability and the apoptotic function of p53 via MDM2. Mol Cell 3:181-193.
28. Neckers L, Ivy SP. 2003. Heat shock protein 90. Curr Opin Oncol 15:419-424.
29. Atadja P, Hsu M, Kwon P, Trogani N, Bhalla K, et al. 2004. Molecular and cellular basis for the anti-proliferative effects of the HDAC inhibitor LAQ824. Novartis Found Symp 259:249-266; discussion 266-268, 285-288.
30. Yu X, Guo ZS, Marcu MG, Neckers L, Nguyen DM, et al. 2002. Modulation of p53, ErbB1, ErbB2, and Raf-1 expression in lung cancer cells by depsipeptide FR901228. J Natl Cancer Inst 94:504-513.
31. Nimmanapalli R, Fuino L, Bali P, Gasparetto M, Glozak M, et al. 2003. Histone deacetylase inhibitor LAQ824 both lowers expression and promotes proteasomal degradation of Bcr-Abl and induces apoptosis of imatinib mesylate-sensitive or-refractory chronic myelogenous leukemia-blast crisis cells. Cancer Res 63:5126-5135.
32. Grossman SR, Deato ME, Brignone C, Chan HM, Kung AL, et al. 2003. Polyubiquitination of p53 by a ubiquitin ligase activity of p300. Science 300:342-344.
33. Pham AD, Sauer F. 2000. Ubiquitin-activating/conjugating activity of TAFII250, a mediator of activation of gene expression in Drosophila. Science 289:2357-2360.
34. Mitsuzawa H, Seino H, Yamao F, Ishihama A. 2001. Two WD repeat-containing TATA-binding protein-associated factors in fission yeast that suppress defects in the anaphase-promoting complex. J Biol Chem 276:17117-17124.
35. Legube G, Linares LK, Lemercier C, Scheffner M, Khochbin S, et al. 2002. Tip60 is targeted to proteasome-mediated degradation by Mdm2 and accumulates after UV irradiation. Embo J 21:1704-1712.
36. Logan IR, Sapountzi V, Gaughan L, Neal DE, Robson CN. 2004. Control of human PIRH2 protein stability: involvement of TIP60 and the proteosome. J Biol Chem 279:11696-11704.
37. Li M, Chen D, Shiloh A, Luo J, Nikolaev AY, et al. 2002. Deubiquitination of p53 by HAUSP is an important pathway for p53 stabilization. Nature 416:648-653.
38. Li M, Brooks CL, Kon N, Gu W. 2004. A dynamic role of HAUSP in the p53-Mdm2 pathway. Mol Cell 13:879-886.
39. Henry KW, Wyce A, Lo WS, Duggan LJ, Emre NC, et al. 2003. Transcriptional activation via sequential histone H2B ubiquitylation and deubiquitylation, mediated by SAGA-associated Ubp8. Genes Dev 17:2648-2663.
40. Daniel JA, Torok MS, Sun ZW, Schieltz D, Allis CD, et al. 2004. Deubiquitination of histone H2B by a yeast acetyltransferase complex regulates transcription. J Biol Chem 279:1867-1871.
41. Kao CF, Hillyer C, Tsukuda T, Henry K, Berger S, et al. 2004. Rad6 plays a role in transcriptional activation through ubiquitylation of histone H2B. Genes Dev 18:184-195.
42. Bach I, Rodriguez-Esteban C, Carriere C, Bhushan A, Krones A, et al. 1999. RLIM inhibits functional activity of LIM homeodomain transcription factors via recruitment of the histone deacetylase complex. Nat Genet 22:394-399.
43. Verdel A, Khochbin S. 1999. Identification of a new family of higher eukaryotic histone deacetylases. Coordinate expression of differentiation- dependent chromatin modifiers. J Biol Chem 274:2440-2445.
44. Matsuyama A, Shimazu T, Sumida Y, Saito A, Yoshimatsu Y, et al. 2002. In vivo destabilization of dynamic microtubules by HDAC6-mediated deacetylation. Embo J 21:6820-6831.
45. Hubbert C, Guardiola A, Shao R, Kawaguchi Y, Ito A, et al. 2002. HDAC6 is a microtubule-associated deacetylase. Nature 417:455-458.
46. Zhang Y, Li N, Caron C, Matthias G, Hess D, et al. 2003. HDAC-6 interacts with and deacetylates tubulin and microtubules in vivo. Embo J 22:1168-1179.
47. Seigneurin-Berny D, Verdel A, Curtet S, Lemercier C, Garin J, et al. 2001. Identification of components of the murine histone deacetylase 6 complex: link between acetylation and ubiquitination signaling pathways. Mol Cell Biol 21:8035-8044.
48. Wojcik C, Yano M, DeMartino GN. 2004. RNA interference of valosin-containing protein (VCP/p97) reveals multiple cellular roles linked to ubiquitin/proteasome-dependent proteolysis. J Cell Sci 117:281-292.
49. Johnson ES, Ma PC, Ota IM, Varshavsky A. 1995. A proteolytic pathway that recognizes ubiquitin as a degradation signal. J Biol Chem 270:17442-17456.
50. Finzer P, Krueger A, Stohr M, Brenner D, Soto U, et al. 2004. HDAC inhibitors trigger apoptosis in HPV-positive cells by inducing the E2F-p73 pathway. Oncogene 23:4807-4817.
51. Li Q, Su A, Chen J, Lefebvre YA, Hache RJ. 2002. Attenuation of glucocorticoid signaling through targeted degradation of p300 via the 26S proteasome pathway. Mol Endocrinol 16:2819-2827.
52. Greene WC, Chen LF. 2004. Regulation of NF-kappaB action by reversible acetylation. Novartis Found Symp 259:208-217.
53. Adam E, Quivy V, Bex F, Chariot A, Collette Y, et al. 2003. Potentiation of tumor necrosis factor-induced NF-kappa B activation by deacetyiase inhibitors is associated with a delayed cytoplasmic reappearance of I kappa B alpha. Mol Cell Biol 23:6200-6209.
54. Kramer OH, Zhu P, Ostendorff HP, Golebiewski M, Tiefenbach J, et al. 2003. The histone deacetylase inhibitor valproic acid selectively induces proteaaomal degradation of HDAC2. Embo J 22:3411-3420.
55. Mitsiades CS, Mitsiades NS, McMuilan CJ, Poulaki V, Shringarpure R, et al. 2004. Transcriptional signature of histone deacetylase inhibition in multiple myeloma: biological and clinical implications. Proc Natl Acad Sci USA 101:540-545.
56. Catley L, Weisberg E, Tai YT, Atadja P, Remiszewski S, et al. 2003. NVP-LAQ824 is a potent novel histone deacetylase inhibitor with significant activity against multiple myeloma. Blood 102:2615-2622.
57. Tan S, Seow TK, Liang RC, Koh S, Lee CP, et al. 2002. Proteome analysis of butyrate-treated human colon cancer cells (HT-29). Int J Cancer 98:523-531.
58. Kopito RR, Sitia R. 2000. Aggresomes and Russell bodies. Symptoms of cellular indigestion? EMBO Rep 1:225-231.
59. Zhou Y, Gu G, Goodlett DR, Zhang T, Pan C, et al. 2004. Analysis of alpha-synuclein-associated proteins by quantitative proteomics. J Biol Chem 279:39155-39164.
60. Hughes RE. 2002. Polyglutamine disease: acetyltransferases awry. Curr Biol 12:R141-143.
61. Thomas M, Dadgar N, Aphale A, Harrell JM, Kunkel R, et al. 2004. Androgen receptor acetylation site mutations cause trafficking defects, misfolding, and aggregation similar to expanded glutamine tracts. J Biol Chem 279:8389-8395.
62. Kawaguchi Y, Kovacs JJ, McLaurin A, Vance JM, Ito A, et al. 2003. The deacetylase HDAC6 regulates aggresome formation and cell viability in response to misfolded protein stress. Cell 115:727-738.
63. Corcoran LJ, Mitchison TJ, Liu Q. 2004. A novel action of histone deacetylase inhibitors in a protein aggresome disease model. Curr Biol 14:488-492.
64. Greer SF, Zika E, Conti B, Zhu XS, Ting JP. 2003. Enhancement of CIITA transcriptional function by ubiquitin. Nat Immunol 4:1074-1082.
65. Brooks CL, Li M, Gu W. 2004. Monoubiquitination: the signal for p53 nuclear export? Cell Cycle 3:436-438.
66. Schwartz DC, Hochstrasser M. 2003. A superfamily of protein tags: ubiquitin, SUMO and related modifiers. Trends Biochem Sci 28:321-328.
67. Mantovani F, Piazza S, Gostissa M, Strano S, Zacchi P, et al. 2004. Pin1 links the activities of c-Abl and p300 in regulating p73 function. Mol Cell 14:625-636.
68. Bernassola F, Salomoni P, Oberst A, Di Como CJ, Pagano M, et al. 2004. Ubiquitin-dependent degradation of p73 is inhibited by PML. J Exp Med 7:1545-1557.
69. Gronroos E, Hellman U, Heldin CH, Ericsson J. 2002. Control of Smad7 stability by competition between acetylation and ubiquitination. Mol Cell 10:483-493.
70. Giandpmenico V, Simonsson M, Gronroos E, Ericsson J. 2003. Coactivator-dependent acetylation stabilizes members of the SREBP family of transcription factors. Mol Cell Biol 23:2587-2599.
71. Fukuoka M, Daitoku H, Hatta M, Matsuzaki N, Umemura S, et al. 2003. Negative regulation of forkhead transcription factor AFX (Fdxo4) by CBP-induced acetylation. Int J Mol Med 12:503-508.
72. Zhao Q, Gumming H, Cerruti L, Cunningham JM, Jane SM. 2004. Site-specific acetylation of the fetal globin activator NF-E4 prevents its ubiquitination and regulates its interaction with the histone deacetylase, HDAC1. J Biol Chem 279:41477-41486.